Top 5 Home Health & Hospice Deals of 2023
The Home Health & Hospice (HH&H) market experienced a decline in deal activity, totaling 95 transactions, compared to the 113 announced in 2022. The deals were evenly distributed throughout the year, with 47 deals announced in the first half of 2023, and 48 deals announced in the second half. However, the larger transactions were announced at the start of the year, with approximately $4.7 billion in announced spending during the first half, and only $32 million announced during the second half, when there were much smaller deals and only one disclosed price. While large buyers dominated the start of the year, smaller buyers took the lead in the latter half. Here are the top... Read More »
2023 Performance Snapshot of Home Health and Hospice Leaders
Explore the financial performance of key players in the Home Health and Hospice (HH&H) sector during 2023. From Amedisys’ steady growth to Addus’ fluctuations, discover the ups and downs, strategic moves and investor interest that defined the industry. 2023 Quarterly Stock Performance of Publicly Traded HH&H Companies: CompanyQ1 2023Q2 2023Q3 2023Q4 2023Amedisys$73.55 $91.44 $93.40 $95.06 Encompass Health$54.10 $67.71 $67.16 $66.72 The Pennant Group$14.28 $12.28 $11.13 $13.92 Addus HomeCare$106.76 $92.70 $85.19 $92.85 Enhabit$13.91 $11.50 $11.25 $10.35 Aveanna... Read More »
UnitedHealth Group Reports 14% Growth YoY, Expands Services & Customer Base
UnitedHealth Group Incorporated (NYSE: UNH), one of the largest health insurers in the United States, reported its third-quarter financial results on Friday, October 13. Last year, the company reported positive performance and balanced growth across its Optum and UnitedHealthcare business segments. This trend has continued into Q3:23, as the company’s growth in the third quarter was attributable to an increase in the number of people served by Optum and UnitedHealthcare, and the broadening scope of services offered. During Q3:23, UnitedHealth reported group revenues of $92.4 billion, up 14% from $80.9 billion in Q3:22. The company also announced Q3:23 earnings from operations of $8.5... Read More »
Q2:23 Thematic Earnings Roundup
This earnings season has provided us with insights into how various publicly traded healthcare companies are navigating the current landscape. Let’s delve into the trends and outcomes that defined the second quarter of 2023. The Home Health & Hospice Market: The Erosion of Medicare Fee-For-Service The Home Health & Hospice (HH&H) market has been volatile of late, with companies like Amedisys Inc. (NASDAQ: AMED) reporting a significant shortfall in earnings and a decline in revenue compared to the same period last year. Amedisys reported a financial loss in the second quarter of $80.3 million, after reporting a profit in the same 2022 period. A significant portion of this... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
